Cutaneous toxicity and management in carcinoembryonic antigen-targeted chimeric antigen receptor T-cell therapy for solid tumours
- 24 November 2025
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 194 (3) , 584-587
Abstract
Cutaneous toxicity following CAR-T therapy is closely linked to immune-cell subset expansion and cytokine dynamics. Prophylactic H1-antihistamines showed effective prevention of rash development, thereby improving the safety profile in solid tumour CAR-T therapy.Keywords
Funding Information
- Taishan Scholar Foundation of Shandong Province (tsqn202312378)
- National Natural Science Foundation of China (81972793)
- National Natural Science Foundation of China (81803400)
This publication has 8 references indexed in Scilit:
- Interleukin‐2‐induced skin inflammationEuropean Journal of Immunology, 2024
- The USP7-STAT3-granzyme-Par-1 axis regulates allergic inflammation by promoting differentiation of IL-5-producing Th2 cellsProceedings of the National Academy of Sciences, 2023
- Cutaneous manifestations of chimeric antigen receptor T-cell therapy: An introduction for dermatologistsJournal of the American Academy of Dermatology, 2022
- The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1Cancer Cell, 2021
- Anti-EGFR chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trialCytotherapy, 2020
- Interleukin-5–producing group 2 innate lymphoid cells control eosinophilia induced by interleukin-2 therapyBlood, 2014
- Chemoattractant Receptors and Lymphocyte Egress from Extralymphoid Tissue: Changing Requirements during the Course of InflammationThe Journal of Immunology, 2010
- CD4+ CD8+ (thymocyte-like) T lymphocytes present in blood and skin from patients with atopic dermatitis suggest immune dysregulationBritish Journal of Dermatology, 2001